Jade Biosciences, Inc.
Jade Therapeutics is a clinical-stage biopharmaceutical company developing novel biologic therapies for patients with autoimmune diseases. The company focuses on discovering and efficiently developing biologics that address emerging therapeutic targets supported by third-party clinical data while overcoming… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Jade Biosciences, Inc. does
In the company’s own words
Jade Therapeutics is a clinical-stage biopharmaceutical company developing novel biologic therapies for patients with autoimmune diseases. The company focuses on discovering and efficiently developing biologics that address emerging therapeutic targets supported by third-party clinical data while overcoming shortcomings of existing product candidates in areas such as potency, bioavailability, formulation, and pharmacokinetic properties.
The company's lead product candidate, JADE101, is a monoclonal antibody targeting APRIL (A PRoliferation Inducing Ligand), a cytokine that modulates plasma cell survival and immunoglobulin production. JADE101 is being developed initially for the treatment of IgA nephropathy (IgAN), the most common primary glomerular disease globally with an estimated prevalence exceeding one million patients worldwide. The company engineered JADE101 to address key limitations of competing anti-APRIL candidates through increased binding affinity and extended pharmacokinetic half-life, designed to support subcutaneous injection every eight weeks or longer. The company initiated a Phase 1 clinical trial of JADE101 in healthy volunteers in New Zealand in August 2025.
The company's second product candidate, JADE201, is a half-life extended, afucosylated monoclonal antibody targeting BAFF-R (B cell activating factor receptor) for treating multiple autoimmune disorders. JADE201 employs a dual mechanism of action, directly killing B cells through antibody-dependent mechanisms while also inhibiting BAFF signaling to block B cell activation and survival pathways. The company plans to initiate a Phase 1 clinical trial of JADE201 in rheumatoid arthritis patients in the second quarter of 2026.
The company's third product candidate, JADE301, targets an undisclosed pathway and is in preclinical development, with Phase 1 initiation expected in the first half of 2027. Jade Therapeutics operates under an exclusive option and license agreement with Paragon Therapeutics, which provides intellectual property rights to the company's antibody candidates. The company was founded in June 2024 and is classified as a smaller reporting company.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1798749
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Jade Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Jade Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Jade Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Jade Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Jade Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”